NEW YORK, NY--(Marketwire - Jan 5, 2012) - The always volatile biotechnology industry had its share of winners and losers last year. Overall, the biotech space was up more than 9 percent in 2011, CNBC reports. However several firms struggled immensely over the last year as disappointing revenues and FDA disappointments weighed down shares of several biotech companies. The BedfordReport examines the outlook for companies in the biotechnology industry and provides investment research onDendreon Corporation (NASDAQ: [ DNDN ]) and AEternaZentaris, Inc. (NASDAQ: [ AEZS ]) (TSX: [ AEZ ]). Access to the full company reports can be found at:

[ www.bedfordreport.com/DNDN ]

[ www.bedfordreport.com/AEZS ]

AEternaZentaris Inc. operates as a late-stage drug development company specialized in oncology and endocrine therapy. The Company's pipeline encompasses compounds at all stages of development, from drug discovery through to marketed products. Last week the company announced that its Japanese partner, Yakult Honsha initiated a Phase 1/2 trial in Japan to assess the safety and efficacy of the Company's PI3K/Akt inhibitor, perifosine, in combination with chemotherapeutic agent, capecitabine, in patients with refractory advanced colorectal cancer.

Last month AEternaZentaris had reported encouraging clinical data for an ongoing Phase 2 clinical study for Perifosine in patients with refractory/relapsed Hodgkin Lymphoma.

The Bedford Report releases stock research on the Biotechnology industry so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at [ www.bedfordreport.com ] and get exclusive access to our numerous stock reports and industry newsletters.

Shares of Dendreon struggled last year as demand for its $93,000 prostate cancer drug, Provenge, was not as strong as expected.

Last month Dendreon agreed to sell its royalty interest related to intellectual property licensed to Schering-Plough Ltd. and Schering Corporation and associated with VICTRELIS (boceprevir), a treatment for chronic hepatitis C, for $125 million in cash. "The sale of the VICTRELIS royalty interest allows the Company to strengthen our cash position, and enables us to further invest in our core business initiatives," said Greg Schiffman, executive vice president and chief financial officer

The Bedford Report provides Market Research focused on equities that offer growth opportunities, value, and strong potential return. We strive to provide the most up-to-date market activities. We constantly create research reports and newsletters for our members. The Bedford Report has not been compensated by any of the above-mentioned companies. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at: [ http://www.bedfordreport.com/disclaimer ]